Homoródi, N.; Varga, É.; Szabó, Z.; Sztanek, F.; Harangi, M.
Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction. Biomedicines 2025, 13, 2595.
https://doi.org/10.3390/biomedicines13112595
AMA Style
Homoródi N, Varga É, Szabó Z, Sztanek F, Harangi M.
Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction. Biomedicines. 2025; 13(11):2595.
https://doi.org/10.3390/biomedicines13112595
Chicago/Turabian Style
Homoródi, Nóra, Éva Varga, Zoltán Szabó, Ferenc Sztanek, and Mariann Harangi.
2025. "Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction" Biomedicines 13, no. 11: 2595.
https://doi.org/10.3390/biomedicines13112595
APA Style
Homoródi, N., Varga, É., Szabó, Z., Sztanek, F., & Harangi, M.
(2025). Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction. Biomedicines, 13(11), 2595.
https://doi.org/10.3390/biomedicines13112595